EUVIMEDEUVIMED entdecken
Kohortenstudie

Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study

Yu-Chen Su, Chin-Yao Shen, Shih-Chieh Shao, Chi-Chun Lai, Sheng-Min Hsu, Chaw-Ning Lee, Chan-Jung Liu, Jia-Horung Hung iD, Edward Chia-Cheng Lai

Age and Ageing · 2024

DOI: 10.1093/ageing/afae155 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Age and Ageing, 2024. Verfasst von Yu-Chen Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: 5-alpha Reductase Inhibitors, Prostatic Hyperplasia, Macular Degeneration, Dutasteride. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Health Research Institutes of Taiwan, National Science and Technology Council of Taiwan, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent studies suggest that 5α-reductase inhibitors (5ARIs) for benign prostate hyperplasia (BPH) result in abnormal retinal anatomical alteration.

Objective

To compare age-related macular degeneration (AMD) incidence in BPH patients receiving 5ARIs or tamsulosin.

Design

Retrospective, population-based cohort study using new-user and active-comparator design.

Setting

General population. Subjects Males with BPH, newly receiving 5ARIs or tamsulosin from 2010 to 2018.

Methods

Data were extracted from Taiwan’s National Health Insurance Research Database. We used Cox proportional hazards model with 1:4 propensity score (PS) matching, based on intention-to-treat analysis to determine the risk of incident AMD. Sensitivity analyses included an as-treated approach and weighting-based PS methods. We also separately reported the risks of incident AMD in patients receiving finasteride and dutasteride to determine risk differences among different 5ARIs.

Results

We included 13 586 5ARIs users (mean age: 69 years) and 54 344 tamsulosin users (mean age: 68.37 years). After a mean follow-up of 3.7 years, no differences were observed in the risk of incident AMD between 5ARIs and tamsulosin users [hazard ratio (HR): 1.06; 95% confidence intervals (95% CI): 0.98–1.15], with similar results from sensitivity analyses. However, increased risk of incident age-related macular degeneration was observed in patients receiving dutasteride [HR: 1.13; 95% CI: 1.02–1.25], but not in those receiving finasteride [HR: 0.99; 95% CI: 0.87–1.12], in the subgroup analyses.

Conclusions

We found no difference between 5ARIs and tamsulosin regarding the incidence of AMD in BPH patients. However, the risk profiles for AMD differed slightly between dutasteride and finasteride, suggesting that the potency of androgen inhibition is a factor related to AMD incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5-alpha Reductase InhibitorsProstatic HyperplasiaMacular DegenerationDutasterideTamsulosinFinasterideHumansMaleAgedRetrospective StudiesTaiwanIncidenceRisk FactorsMiddle AgedRisk AssessmentDatabases, Factual

Stichwörter der Autor:innen

5α-reductase inhibitorsage-related macular degenerationbenign prostate hyperplasiaolder peopletamsulosin

Substanzen

5-alpha Reductase InhibitorsDutasterideTamsulosinFinasteride

Autor:innen und Institutionen

  • Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
  • School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Ophthalmology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.

ORCID-Profile: Jia-Horung Hung

Förderung

  • National Health Research Institutes of Taiwan
  • National Science and Technology Council of Taiwan
  • Ministry of Science and Technology
  • National Cheng Kung University Hospital

Zitieren

APA

Su, Y. C., Shen, C. Y., Shao, S. C., Lai, C. C., Hsu, S. M., Lee, C. N., Liu, C. J., Hung, J. H., & Lai, E. C. (2024). Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study. Age and Ageing. https://doi.org/10.1093/ageing/afae155

Vancouver

Su YC, Shen CY, Shao SC, Lai CC, Hsu SM, Lee CN, et al. Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study. Age and Ageing. 2024. doi:10.1093/ageing/afae155

BibTeX
@article{Su2024,
  author = {Su, Yu-Chen and Shen, Chin-Yao and Shao, Shih-Chieh and Lai, Chi-Chun and Hsu, Sheng-Min and Lee, Chaw-Ning and Liu, Chan-Jung and Hung, Jia-Horung and Lai, Edward Chia-Cheng},
  title = {Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study},
  journal = {Age and Ageing},
  year = {2024},
  doi = {10.1093/ageing/afae155}
}
Kostenlos starten →